Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Impact on insulin secretion determined by 2-hour MMTT stimulated AUC C-peptide 10 weeks after first vedolizumab dose and 52 weeks after randomization.
研究概览
简要总结
The underlying hypothesis is that vedolizumab will modify immune cell trafficking in type 1 diabetes, and that this will be enhanced by pre-treatment with etanercept. This study will determine whether there is mechanistic evidence in support of this hypothesis and provide preliminary information about safety, efficacy, and tolerability of vedolizumab with and without pretreatment with etanercept in adults with type 1 diabetes (T1D)
详细描述
Vedolizumab directly blocks integrin α4ß7 on circulating immune cells preventing their egress from the blood, while etanercept blocks the TNFα signaling necessary for the α4ß7 cognate addressin MAdCAM-1 to be expressed in pancreatic endothelial cells. For these reasons, the investigators hypothesize that the two agents may synergistically prevent diabetogenic immune cells from trafficking from the periphery to their target tissue to cause islet cell destruction. Cells from both the myeloid (e.g., myeloid DC1 cells and non-classical monocytes) and lymphoid compartments (e.g., diabetes antigen-specific T cells) would be impacted by this therapeutic combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 18-45 years of age, inclusive
- •Diagnosis of T1D between 21 days and 3 years from screening
- •Positive for at least one diabetes-related autoantibody any time since diagnosis, including but not limited to:
- •Glutamate decarboxylase (GAD-65)
- •mIAA, if obtained within 10 days of the onset of exogenous insulin therapy
- •ZnT8 (Zinc transporter 8)
- •Random (non-fasting) C-peptide or peak MMTT stimulated C-peptide ≥ 0.2 pmol/mL.
- •Females of child-bearing potential must be willing to use effective birth control from the screening visit through 12 weeks post last dose of study medication.
- •Up to date for clinically recommended immunizations including COVID-19 and seasonal influenza vaccine at least 3 weeks prior to baseline treatment.
- •Willing to forgo live vaccines 6 weeks prior to baseline treatment visit until 6 weeks following last treatment visit.
- •HbA1c ≤ 8.5% at screening
- •Willing and able to give informed consent for participation
排除标准
- •History of severe reaction or anaphylaxis to human, humanized or murine monoclonal antibodies
- •History of malignancy or serious uncontrolled cardiovascular, nervous system, pulmonary, renal, or gastrointestinal disease
- •History of immunodeficiency
- •Recent (within 3 months) serious bacterial, viral, fungal, or other infections
- •Pending or positive SARS-CoV-2 test or symptoms of possible COVID-19 illness at baseline treatment visit.
- •Serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C.
- •Positive QuantiFERON or PPD TB test, history of tuberculosis, or active TB infection.
- •Active infection with EBV as defined by real-time polymerase chain reaction (PCR).
- •Active infection with CMV as defined by real-time PCR.
- •Clinically significant liver function abnormalities as defined by ALT or AST> 1.5 x the upper limit of age-determined normal (ULN).
- •Any of the following hematologic abnormalities:
- •White blood count <3,000/μL or >14,000/μL
- •Lymphocyte count <800/μL
- •Platelet count <75,000 /μL
- •Hemoglobin <10.0 g/dL
- •Neutrophil count <1500 cells/μL
- •Females who are pregnant or lactating.
- •Receipt of live vaccine (e.g., varicella, MMR (measles, mumps and rubella), intranasal influenza vaccine) within 6 weeks of randomization.
- •Receipt of other vaccines within 3 weeks of baseline treatment.
- •Receipt of an immune modulating biologic or investigational drug within 3 months or 5 half-lives before screening visit.
- •Use of non-insulin therapies aimed to control hyperglycemia within 30 days of screening visit.
- •History of other clinically significant autoimmune disease needing chronic therapy with biologics or steroids with the exception of celiac disease and stable thyroid disease.
- •Use of medications known to influence glucose tolerance. Topical, nasal, inhaled corticosteroids acceptable per investigator discretion.
- •Any medical or psychological condition that in the opinion of the principal investigator would interfere with the safe completion of the trial.
研究组 & 干预措施
Arm A
Arm A will receive 6 weeks of vedolizumab after 8 weeks of etanercept. Final study visit at 52 weeks.
干预措施: Etanercept (Drug)
Arm A
Arm A will receive 6 weeks of vedolizumab after 8 weeks of etanercept. Final study visit at 52 weeks.
干预措施: Vedolizumab (Drug)
Arm B
Arm B will receive 6 weeks of vedolizumab only. Final study visit at 52 weeks.
干预措施: Vedolizumab (Drug)
结局指标
主要结局
Impact on insulin secretion determined by 2-hour MMTT stimulated AUC C-peptide 10 weeks after first vedolizumab dose and 52 weeks after randomization.
时间窗: baseline dose to 10 weeks and baseline dose to 52 weeks
MMTT-Stimulated 2-Hour C-peptide AUC is the mean area under the C-peptide level time curve over the 2-hour period divided by the duration after a mixed-meal tolerance test.
Adverse events of vedolizumab treatment as a measure of safety and tolerability
时间窗: baseline to 52 weeks
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Results will be reported as a rate of each adverse event
Adverse events of etanercept treatment as a measure of safety and tolerability
时间窗: baseline to 52 weeks
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. Results will be reported as a rate of each adverse event
次要结局
- Frequency of α4β7+ T cells(baseline to 52 weeks)
- Frequency of myeloid DC1 cells(baseline to 52 weeks)
- Frequency and surface marker phenotype of other immune cells such as antigen specific CD4 and CD8 cells, memory and naive T and B cells(baseline to 52 weeks)
- Change in T1D antibody titers(baseline to 52 weeks)